This phase II trial is trying to understand the safety and potential impact of adding radiotherapy to standard hormone therapy in patients with castration resistant prostate cancer that has not previously been treated using chemotherapy and has spread to other parts of the body.
This trial is treating patients with castration resistant prostate cancer.
This is a radiotherapy and systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide
Australian & New Zealand Urogenital and Prostate Cancer Trials Group Limited (ANZUP)
Other Non-Commercial Sponsor
National Health & Medical Research Council (NHMRC)
Eligible patients will be randomised to receive 160mg of oral enzalutamide daily, alone or in combination with Lu-PSMA.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More